- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01402024
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy (Aprepitant)
A Study to Evaluate the Anti-emetic Effect of Aprepitant Versus Placebo as an Add-on Therapy in Children and Adolescent Receiving Chemotherapy: A Randomized, Doubly Blinded Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Population:
Children and adolescents (5-18 years) with weight between 15-65 kg receiving highly emetogenic chemotherapy (HEC) -
- VAC (vincristine, dactinomycin/Adriamycin, cyclophosphamide)
- ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
- Cisplatin/Doxorubicin
Sampling technique Subjects who met the eligibility criteria will be randomly assigned using random allocation number generated by computer into one of the two groups. The unit of randomization will be the subject at first cycle of HEC. The same patient will not be enrolled for twice
Procedure for data collection:
- The data will be collected from each patient from d1 to d10 of chemotherapy of which patient will received chemotherapy in day care, maximum up to d3.
- After taking consent patient will be enrolled as per inclusion and exclusion criteria, and randomized to one of two groups. All baseline assessment will be done. Patient will be explained about the filling of the diary. In first 2 days. The subjects will fill the diary under the investigator supervision, and the rest of filling will be in home. Reinforcement will be done over phone.
Procedure of double blinding
- Double blinding will be done for the intervention. Four different boxes will be made for capsules. Total 3 capsules for 3 days will be made in a blister pack, mentioning the d1, d2, d3 (for each capsule). Two different body weight groups will be made: 15-40 kg, and 41-65 kg.
- Group "A" will be the code for Aprepitant group and group "B" will be code for control group. Both patient and the investigator will be blinded regarding medicine in the code.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110029
- Dr. BRA IRCH, AIIMS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All subjects must have a confirmed diagnosis of malignancy and receiving highly emetogenic chemotherapy first time (VAC, ABVD and CDDP/Doxorubicin)
- Age group 5-18 years with weight between 15-65 kg
- Children/adolescents and their caregiver who can understand Hindi or English and willing to participate in the study (with written informed consent)
Exclusion Criteria:
- Significant organ dysfunction
- Active infection
- Pregnancy
- Uncontrolled medical condition other than malignancy
- Need for contraindicated concomitant medication
- Patients receiving chemotherapy other than VAC, ABVD and CDDP/Doxorubicin
- Treatment with another investigational drug within 4 weeks of study start or prior Aprepitant use
- Had received or will receive RT to abdomen or pelvis in the week prior to treatment
- Vomited in the 24 hr prior to treatment
- Prior exposure to highly emetogenic chemotherapeutics
- Abnormal lab values (ANC<1500/mm3, TLC<3000/mm3, Plt<100,000/mm3, AST/ALT> 2.5 times of ULN, bill>1.5 times of ULN, S.cr>1.5 times of ULN, patient on systemic steroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aprepitant
It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy.
Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm.
The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
|
The patient on study group with weight category of 15-40 kg will receive: D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and The patient with weight category of 41-65 kg in study group will receive: D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg
Other Names:
|
Placebo Comparator: Control
It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy.
Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm.
The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
|
Patient on control group with weight category of 15-40 kg will receive: D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and The patient on control group with weight category of 41-65 kg will receive: D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
- Numbers of episodes of nausea and vomiting. - Duration of nausea (in hours). - Severity of nausea as per Edmonton's Symptom Assessment System (ESAS), numerical scale for nausea.
Time Frame: 5 days
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
- Chemotherapy induced additional side effects. - Number of anti-emetic dosage (other than aprepitant) required for treatment of vomiting.
Time Frame: 5 days
|
5 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sameer Bakhshi, MD, Dr. BRA IRCH, AIIMS, New Delhi (India)
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT/38/011/RS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy Induced Nausea and Vomiting
-
GlaxoSmithKlineCompletedChemotherapy-Induced Nausea and Vomiting | Nausea and Vomiting, Chemotherapy-InducedTaiwan, United States, Germany, Russian Federation, Spain, Ireland, Thailand, Hong Kong, Mexico, Philippines, Austria, Chile, Greece, Poland, Canada, Czech Republic, United Kingdom, Hungary, Pakistan, Slovakia, Singapore, Portugal, ... and more
-
Blokhin's Russian Cancer Research CenterRUSSCO/RakFondUnknownChemotherapy-induced Nausea and Vomiting | Nausea | Vomiting | Emesis | Nausea Post ChemotherapyRussian Federation
-
Otolith LabsDrexel University College of MedicineWithdrawnChemotherapy-induced Nausea and Vomiting | Nausea Post ChemotherapyUnited States
-
Indonesia UniversityMashhad University of Medical SciencesRecruitingChemotherapy-induced Nausea and Vomiting | Chemotherapy Effect | Pediatric CancerIndonesia
-
Joseph MaTerminatedChemotherapy Induced Nausea Vomiting
-
Fudan UniversityNot yet recruitingChemotherapy-induced Nausea and Vomiting | Highly Emetogenic Chemotherapy
-
Simon Williamson ClinicHelsinn Healthcare SARecruitingChemotherapy Induced Nausea and VomitingUnited States
-
University of Illinois at ChicagoRecruitingChemotherapy-induced Nausea and VomitingUnited States
-
Antje KollerUniversity Medical Center Freiburg; ZETUP St. Gallen; Dr.-Hans-Altschüler-Sti... and other collaboratorsCompletedChemotherapy-induced Nausea and VomitingSwitzerland
-
Albert Einstein College of MedicineJacobi Medical CenterTerminatedChemotherapy-induced Nausea and VomitingUnited States
Clinical Trials on Aprepitant
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting
-
Merck Sharp & Dohme LLCCompletedChemotherapy Induced Nausea and Vomiting
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
-
The Hospital for Sick ChildrenCompletedChemotherapy-induced Nausea and VomitingCanada
-
University of VirginiaNational Institute on Drug Abuse (NIDA)CompletedCannabis Dependence | Nicotine Dependence | Marijuana Dependence | Cannabis Abuse | Nicotine WithdrawalUnited States
-
University Hospital, RouenCompleted
-
Sharon WalshNational Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLCCompleted
-
Duke UniversityMerck Sharp & Dohme LLCCompleted
-
University Hospital Inselspital, BerneRecruitingPostoperative Nausea and Vomiting | Bariatric SurgerySwitzerland